Skip to main content
TITAN PHARMACEUTICALS INC logo

TITAN PHARMACEUTICALS INC — Investor Relations & Filings

Ticker · TTNP ISIN · US8883146065 LEI · 549300NOUZGB2ZNVJ794 US Manufacturing
Open in API
Filings indexed 1,000 across all filing types
Latest filing 2012-10-11 Regulatory Filings
Country US United States of America
Listing US TTNP

About TITAN PHARMACEUTICALS INC

https://www.titanpharm.com/

Titan Pharmaceuticals, Inc. is a development-stage biopharmaceutical company that develops proprietary therapeutics using its clinically proven ProNeura® technology, a long-term, continuous drug delivery platform. This platform is designed for the administration of medicines to treat select chronic diseases. The ProNeura system involves a small, solid implant that is placed subdermally and provides continuous, non-fluctuating blood levels of a drug for an extended period. The company's development efforts have historically focused on treatments for central nervous system disorders.

Recent filings

Filing Released Lang Actions
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The content describes an event where Novartis decided to cease development of a drug formulation and discusses royalty arrangements. The document is short (2760 characters) and serves as an announcement of a material event rather than a detailed financial report or other specific filing type. It does not contain financial statements, management discussion, or detailed presentations. Therefore, it fits the category of a Regulatory Filing (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2012-10-11 English
FORM 8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The content describes an unregistered sale of equity securities (private placement of common stock) and references a Stock Purchase and Option Agreement. It includes details about the transaction but does not contain comprehensive financial statements or detailed financial analysis. The document is relatively short (3093 characters) and includes a press release as an exhibit. This type of filing is best classified as a Capital/Financing Update (CAP) because it reports on a financing transaction involving the sale of shares and an option agreement. It is not an Annual Report, Earnings Release, or other report types. Therefore, the appropriate classification is CAP with high confidence.
2012-09-14 English
FORM 10-Q
Interim / Quarterly Report Q2 2012
2012-08-09 English
FILED PURSUANT TO RULE 424(B)(3)
Capital/Financing Update Classification · 95% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(3) related to a securities offering by Titan Pharmaceuticals, Inc. It details the resale of shares by selling stockholders, amendments to exercise prices of warrants, and registration statements. The content focuses on capital raising activities, share offerings, and related disclosures. It is not a financial report, earnings release, or management discussion, but rather an update on financing and securities registration. Therefore, the document fits the category of Capital/Financing Update (CAP). The document length and detailed offering information support this classification with high confidence.
2012-05-24 English
FORM 10-Q
Interim / Quarterly Report Q1 2012
2012-05-10 English
FORM 8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K, which is a current report filed with the SEC to announce major events that shareholders should know about. The text mentions a letter to stockholders discussing a recent registered direct offering, which is a financing activity. The document is short (2491 characters) and primarily announces the letter posted on the company's website. It does not contain detailed financial statements or comprehensive financial data. Therefore, it is an announcement related to capital raising activities rather than a full financial report. According to the filing definitions, updates on company fundraising or financing activities are classified as Capital/Financing Update (CAP).
2012-04-17 English

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.